Daglozin M 5/850mg Tablet

Daglozin M 5/850mg Tablet is a combination medication containing two active ingredients: Dapagliflozin & Metformin Hydrochloride (HCI). Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, while Metformin HCI is a biguanide antidiabetic medication. This tablet is prescribed for the management of type 2 diabetes mellitus in adults, helping to control blood sugar levels through different mechanisms of action.

Uses:

Daglozin M 5/850mg Tablet is used to improve glycemic control in adults with type 2 diabetes mellitus. Dapagliflozin works by inhibiting the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine and lowering blood sugar levels. Metformin HCI decreases hepatic glucose production, improves insulin sensitivity, and enhances peripheral glucose uptake, further contributing to glycemic control. Together, these medications help improve glycemic control and may also promote weight loss.

Dosage:

The dosage of Daglozin M 5/850mg Tablet is determined by the healthcare provider based on factors such as the patient’s medical history, renal function, and response to treatment. It is typically taken orally twice daily with meals to reduce the risk of gastrointestinal side effects associated with Metformin HCI. The tablet should be swallowed whole with a glass of water and should not be crushed or chewed.

Side Effects:

Common side effects associated with Daglozin M 5/850mg Tablet may include urinary tract infections, genital yeast infections, increased urination, thirst, dizziness, nausea, diarrhea, abdominal discomfort, and headache. These side effects are usually mild and transient. In some cases, more serious side effects such as hypoglycemia (low blood sugar), ketoacidosis, or allergic reactions may occur. Patients should report any adverse reactions to their healthcare provider promptly.

Precautions:

Before using Daglozin M 5/850mg Tablet, patients should inform their healthcare provider about any pre-existing medical conditions, allergies, or medications they are currently taking. This medication may interact with other drugs, so it’s essential to review the patient’s medication regimen to avoid potential interactions. Patients with impaired renal function or a history of ketoacidosis should use Daglozin M with caution.

When Not to Use:

Daglozin M 5/850mg Tablet is contraindicated in patients with a known hypersensitivity to Dapagliflozin, Metformin HCI, or any other components of the medication. It should not be used in patients with type 1 diabetes mellitus or diabetic ketoacidosis. Patients with severe renal impairment, end-stage renal disease, or a history of lactic acidosis should also avoid this medication.